Europe’s high court strikes blow to drug companies in ‘pay-for-delay’ case
By 
Jaclyn Jaeger2020-01-30T21:47:00
The U.K. Competition and Markets Authority won a victory in a decision by Europe’s high court, ruling GlaxosmithKline’s entering of a financial deal with industry rivals to delay the generic version of its drugs violates EU competition law.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleFTC, FDA to enhance antitrust oversight in biologics market
The Federal Trade Commission and Food and Drug Administration have signaled they will be increasing their oversight of any potential antitrust behavior in the biologics market.
-
PremiumDelayed UK antitrust case underscores compliance, reputational risks
Antitrust infringement cases in the United Kingdom can run on for years, but there’s a question whether issuing fines that are dwarfed by the revenues of those organisations involved is a worthy deterrent—particularly if they are imposed over a decade after the misconduct ended. It’s also debatable whether the first ...
-
PremiumEllen Hunt, CW’s 2025 Lifetime Achievement Award winner
Ellen M. Hunt, CW’s 2025 Lifetime Achievement Award winner, is a torchbearer for the profession and a beloved role model in E&C circles. Lauded for her generosity of spirit, quick wit, and tireless mentorship, the ethics and compliance veteran turned compliance from a patchwork assignment to a true vocation. ...
More from Europe
-
ArticleExperts: P&O Ferries’ exposure of U.K. law weaknesses sets dangerous precedent
P&O Ferries’ dismissal of 800 workers with immediate effect via prerecorded video before consulting unions or employees has united U.K. politicians of all parties to condemn the company. One problem: Its actions appear to be largely legal.
-
ArticleAmazon shuttered in France over COVID-19 emergency costs
E-commerce giant Amazon has shut up shop in France because the cost of compliance with the country’s COVID-19 emergency measures is deemed to be too high.
-
ArticleDon’t count on European regulators to relax rules during coronavirus crisis
European businesses may be putting themselves at risk because they mistakenly believe regulators are prepared to loosen the rules so companies can operate more easily as the coronavirus pandemic lingers on.